Eftilagimod alfa is under clinical development by Immutep and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eftilagimod alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Eftilagimod alfa overview

eftilagimod alfa (IMP-321, EDP-202) is under development for the treatment of HER2-negative hormone receptor-positive metastatic breast cancer, soft tissue sarcoma, peritoneal cancer, triple-negative breast cancer, non-small cell lung cancer, recurrent head and neck cancer squamous cell carcinoma, as an adjuvant therapy for metastatic melanoma, hepatocellular carcinoma, metastatic urothelial cancer and solid tumors. It is administered through subcutaneous, intratumoral and intraperitoneal routes. It is a recombinant soluble human lymphocyte-activation gene 3 (LAG-3) IgG Fc fusion protein. The drug candidate is developed by using ImmuFact technology.

The drug candidate was also under development for hepatitis B, pancreatic adenocarcinoma, unspecified influenza virus infection, metastatic renal cell carcinoma, coronavirus disease 2019 and prostate cancer.

Immutep overview

Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company collaborates with pharmaceutical and biotech companies for research and development activities. It has operations in Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.

For a complete picture of Eftilagimod alfa’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.